Omeros Gets FDA Rare Pediatric Disease Designation for Renal Disorder Treatment

Seeking AlphaOct 24 21:13

Express News | FDA Grants Rare Pediatric Disease Designation to Omeros’ Masp-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy

BreakingsOct 24 20:45

Needham Sticks to Its Hold Rating for Omeros (OMER)

TipRanksAug 8 20:02

Omeros | 10-Q: Q2 2024 Earnings Report

SECAug 8 04:15 · Announcements

Express News | Omeros Corporation Reports Second Quarter 2024 Financial Results

BreakingsAug 8 04:02

Express News | Omeros Corporation Q2 Net Income USD -56 Million

BreakingsAug 8 04:02